Articles On PainChek (ASX:PCK)

SYDNEY, Oct. 16, 2021 /PRNewswire/ — Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has i...

S&P 500 closed at record high again Wall Street closed Friday mostly on a high note, with the S&P 500 once again reaching an all-time high. The S&P 500 climbed by 0.33%, the Dow Jones rose by 0.69%, but tech heavy Nasdaq fell sl...

A big surge in energy shares led the ASX into positive territory for the second day in a row. The ASX 200 closed 0.59 per cent higher at 7,260 points although the ASX Emerging Companies Index closed 0.28 per cent lower at 2,188. Energy led...

Summary Day after scaling a record high level, the ASX 200 on Thursday again opened higher. The investors were upbeat on strong GDP data. On Wednesday, the benchmark Australian index ended 1.05% higher at 7,217.80. The Australian...

There are 50 million people living with dementia and 400 million pre-verbal children, at any given point in time. Despite being in the opposite stages of life, both groups actually have something in common – they have difficulty in reliably...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Shares in PainChek Ltd (ASX: PCK) are gaining today after news the company has received regulatory clearances for its app, PainChek Infant. At the time of writing, the PainChek share price is up 6.15%, with shares in the company swapping h...

Summary Advanced Human Imaging has entered into a binding agreement with Jana Care to bring affordable digitally connected care to everyone. PainChek Infant has obtained the necessary regulatory approvals in multiple International mark...

It was a good morning for shareholders of PainChek (ASX:PCK) and Advanced Human Imaging (ASX:AHI), a pair of companies using smartphone technology to detect ailments. The companies, aspiring to go global, informed shareholders of major deve...

Wall Street slips for third consecutive day Inflation worries have persisted in the market, with all major indices in the US falling again overnight, bringing the string of losses to three consecutive days. The Dow Jones was down 0.48%, S&a...

There were only nice surprises in the aged-care funding announced by the Treasurer last night, with the government seemingly set to overhaul the sector with a $17.7 billion cash-splash over the next five years. Roughly a third of that will...

Summary With the current emergency, it is anticipated that telehealth or telemedicine could be the future of medicine. COVID-19 pandemic resulted in considerable adoption of telehealth solutions, mainly to avoid physical contact. The...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

The PainChek Ltd (ASX: PCK) share price is soaring today after the company announced it has received approvals for its latest pain monitoring app update. At the time of writing, the mobile medical app developer’s shares are up 13% to 7.8 c...

Source:MonsterStudio,Shutterstock Summary Mobile-based healthcare technology developer PainChek has obtained CE Mark and TGA approval for its Universal app. PainChek to launch its Universal app across Australia and the UK from April 2...

PainChek (ASX:PCK) says it has received regulatory approval to market the next generation of its pain-detecting smartphone app in Europe, the United Kingdom and Australia. The company has received CE Mark clearance in Europe and Therapeutic...

Wall Street pulls back Blue chip Dow Jones finally had an off-day, falling by 0.39% after reaching consecutive record highs in the last few days. S&P 500 also fell by 0.16%, while tech heavy NASDAQ rose slightly by 0.09%. The major tech...

Peter Switzer is joined by Philip Daffas, the CEO and Managing Director of Painchek (PCK).

ShareCafeHidden Gems Webinar Recap – PCK, CV1, GLN, CE1 – 26/2/21 Catch up on the full webinar with presentations from Painchek (ASX:PCK), CV Check (ASX:CV1), Galan Lithium (ASX:GLN), Calima Energy (ASX:CE1) Hidden Gems Webinar Recap – PCK...

ShareCafePainChek (ASX:PCK) – Hidden Gems Webinar Presentation Presenter – Philip Daffas – CEO & Director – PainChek is transforming pain management to help give a voice to those who cannot verbalise their pain. PainChek uses facial re...

The PainChek Ltd (ASX: PCK) share price was among the few ASX shares that stayed in the green today, closing up 2.56% at 8 cents. The share price increase came off the back of the company half-year report announced to the market yesterday....

Next week marks one year since the S&P/ASX All Technology Index (ASX: XTX) debuted. Launched at the end of February 2020, the All Technology Index debuted just in time for the March market meltdown. The index saw its value tumble 42%...

The Painchek Ltd (ASX: PCK) share price climbed today after the company provided the market with a positive quarterly update for December 2020. Shares in the small cap healthcare company were trading 4.2% higher at 7.4 cents on close of tr...

Summary PainChek® has completed PainChek Infant Face-Only clinical trial to support regulatory clearance in Australia and Europe. PainChek delivers on sales growth during aged care lock-down while continuing market expansion. In Decem...

It’s been another positive day on the ASX in the wake of Democrats gaining control of the US Senate – but small caps have once again underperformed their larger peers. The Small Ordinaries index of 200 small-cap companies closed Friday up 1...

The PainChek Ltd (ASX: PCK) share price is dropping lower on Friday morning following the release of an announcement. In morning trade the healthcare technology company’s shares are down 3% to 9.2 cents. What did PainChek announce? Investo...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment ... Read More The post Health Kick Podcast: PainChek’s AI-backed pain assessment tech a game-changer for...

The ASX200 rose 2.2% in August with technology and consumer discretionary leading the way during the reporting season, while further trading updates are expected during the upcoming AGM season. –The ASX200 climbed 2.2% during August, gainin...

ShareCafePainChek – ShareCafe Hidden Gems Webinar Presentation   Presenter – Philip Daffas – CEO & MD – PainChek® is the world’s first pain assessment tool that has regulatory clearance in Australia and Europe. Using AI and facial reco...

ShareCafeHidden Gems Webinar Recap – PCK, WOA, PYG, AJQ   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from PainChek (ASX: PCK), Wide Open Agriculture...

Mobile medical device outfit PainChek was out hunting for fresh capital on Friday to finance taking its adult dementia mobile application overseas.

Telehealth use has only continued to increase as COVID-19 wore on throughout May and June. Both listed and non-listed plays such as healthcare booking service HealthEngine saw demand rise exponentially as the pandemic broke out and this has...

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more often than not...

Almost all of the ASX’s health small caps have visions as ambitious as the Australian and state governments’ broader health objectives for society as a whole. The combined market caps of all ASX health companies under $500m is approximately...

Last year was a solid year for many ASX stocks and 2020 was also looking pretty good until COVID-19 struck the markets in late February. Earlier this week Reuben Adams recapped which of last year’s top mining and exploration companies have...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 59 were in positive territory over the last fortnight, 22 were flat and 58 saw t...

08 May 2020 - PainChek® (ASX:PCK) has received a notice of allowance from the Australian Patent Office for its pain assessment invention.

Today Stockhead has gone through the best and worst 4C releases so you don’t have to. And tech companies were among the standouts today.   CV Check (ASX:CV1) As its name suggests, this company’s bread and butter is checking CVs. It surpasse...

Australian medical device company PainChek (ASX: PCK) has reported a strong performance for the March quarter with much of its growth being driven by the country’s residential aged care sector. PainChek’s smartphone-based pain assessment te...

Mobile medical app developer Painchek Ltd [ASX:PCK] has seen its share price jump 13.24% today, up 0.9 cents to trade at 7.7 cents per share. The post PainChek Share Price Up 13% As Healthcare Sector Soars appeared first on Money Morning Au...

Medical device company PainChek (ASX: PCK) confirmed it has met an important 25,000 licenced bed milestone under a $5 million grant agreement with the Australian Federal Government. In total, PainChek achieved more than 44,000 licenced beds...

Dementia already affects hundreds of thousands of people in Australia, and it’s only going to get worse if a medical miracle is not forthcoming. The term relates to brain diseases, including Alzheimers, that impact a person’s ability to thi...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Australian company PainChek (ASX:PCK) says it been granted a patent in Japan for its smartphone pain assessment and monitoring technology.

The European Commission has granted Orphan drug status for Alterity Therapeutics’ (ASX:ATH) lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). That gives Alterity 10 years of market exclusivity in the European Union...

It’s fair to assume PainChek (ASX:PCK) shareholders are a happy bunch with a 12-month share price rise of 413 per cent. The rise of the pain-detection app company began in late April thanks to a $5m investment from the Morrison government....

As the year winds down and AGM season concludes brokers have been busy filling their Christmas stockings with stock picks they think will be winners. Here are five predictions made in the last week that stood out: 1. Navarre Minerals (ASX:N...

Australian medical device company PainChek (ASX: PCK) is expanding its presence in the UK market, making its first direct sale and confirming first orders for the region. PainChek has developed a smartphone-based medical device using artifi...

PainChek Limited (ASX: PCK) has received first 1,000 PainChek annual bed license order from Person Centred Software UK (PCS UK). The collaboration with PCS provides immediate access to 1500 homes but more crucially, a significantly higher p...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...